Additionally, EGR1 has been identified in both the suppression and progression of tumors (reviewed in [15]), with high expression of EGR1 being observed in several different cancers, such as glioma, lung, ovarian, and prostate cancer [15–22]. Here, EGR1 is linked to prostate carcinoma.